Introduction
Rubinstein -Taybi syndrome (RSTS) is a well-known autosomal-dominant disorder of typical face, short stature, skeletal abnormalities, and mental retardation, and was shown to be caused in most cases by mutations in CREBBP, the gene for CREB binding protein. 1 -3 Approximately 45 -56% of patients with RSTS demonstrated CREBBP mutations, 2, 3 and recently, three individuals with EP300 gene mutations were reported in a series of 92 patients. 4 The EP300 gene on chromosome 22q13 encodes a protein, p300, that is highly similar to CREBBP. Both CREBBP and p300 are transcriptional coactivators with a plant homeodomain-type zinc finger and a histone acetyl transferase (HAT) domain facilitating chromatin opening. 5, 6 They are involved in the regulation of the expression of numerous genes that are important in embryonic development, cell growth, cellular differentiation, and tumor suppression. 7 -10 Despite many similarities, CREBBP and p300 are involved in slightly different signal-transduction pathways. 7,9 -12 The first report of EP300 mutations in RSTS 4 required a confirmational study (performed here) and raised new questions, for example, regarding the frequency of EP300 mutations in RSTS, the causes of the paucity of EP300 vs CREBBP mutations, the phenotypic spectrum in humans with EP300 mutations, and possible further genetic heterogeneity in RSTS.
Using genomic sequencing and real-time quantitative PCR (qPCR) we studied 13 patients (out of a series of 38 patients previously reported after fluorescence in situ hybridization (FISH) and genomic sequencing of CREBBP), 3 for the presence of EP300 mutations and CREBBP deletions that had escaped detection by FISH.
We identified two novel mutations, a 1-bp deletion (c.7100delC) in EP300 and a CREBBP deletion including exons 28 and 31. The EP300 gene mutation predicts a very mildly truncated protein and does not alter the HAT domain, which elsewhere had been shown to be critical in causing RSTS. 5, 6 Based on the location of the EP300 gene mutations 4 (also this study), the relatively large number of single-nucleotide polymorphisms (SNPs; 2.33 per patient), and the observed (although not very striking) phenotypical differences with the EP300 mutations detected so far 4 (also this study), we suggest that mutations in EP300 could be underdiagnosed because they may result in phenotypes different from RSTS. Finally, we identified in EP300 a homozygous sequence variation (c.2053 þ 8T) that was present in all individuals studied and therefore most likely represents the wild-type sequence.
Materials and methods
Out of a series of 38 previously reported patients, we studied here 13 of 19 patients in whom no CREBBP mutation had been identified. 3 Of these, 10 individuals had RSTS and three had a diagnosis of incomplete RSTS (see 3 for definition). From the other six patients without detectable CREBBP mutation, there was not enough DNA at disposal. We used genomic sequencing and real-time qPCR 13, 14 for the detection of molecular EP300 mutations and partial deletions of CREBBP and EP300, respectively. The 31 coding exons of EP300 were analyzed in 37 fragments (Table 1 ) using a previously described protocol 3, 15 and a CEQt 8000 Genetic Analyzer (Beckman Coulter, Fullerton, CA, USA). All sequence variations were confirmed in a second PCR and sequencing run. The EP300 gene mutation identified here was proven to be de novo by sequencing of DNA from the parents. Paternity testing was not performed due to legal restrictions. The Entrez SNP Database was consulted for interpretation of SNPs. The qPCR was performed using a total of 18 different amplicons (CREBBP: intron 1, exon 2, introns 2 -3, exon 3, introns 4 -5, exon 6, exon 14, exon 16, exon 28, and exon 31; EP300: exons 1, 2, 4, intron 9, and exons 14, 18, 25, and 31) and a previously described protocol. 13 Note that CREBBP and EP300 exon numbers are in line with the literature, 1 -6 but differ by À1 from actual exon numbers.
Results
We identified two mutations. In patient 12 described below, genomic sequencing of EP300 revealed a 1-bp deletion, c.7100delC (p.P2366fsX2401; Figure 1 ). In patient 21, a 21-year-old woman with RSTS (A-1928 -22 in our previous study), 3 qPCR indicated a deletion of CREBBP at exons 28 and 31. Thus, the CREBBP mutation detection rate increased to 52.6% (20 in 38) in our whole series of patients, or to 60% (18 in 30) in the subset of patients with unequivocal RSTS only. We also detected five different SNPs in the EP300 gene (Table 2) , all previously reported, including non-synonymous SNPs in exons 3 (c.865A-G, p.M289V, rs2230111) and 15 (c.2989A-G, p.I997V, rs20551), a synonymous SNP in exon 17 (c.3183A-T, rs4822012), and two intronic variants (introns 27 -28, c.4452 þ 20C-T, rs6002271; introns 28 -29, c.4618 -18C-T, rs2076578). Moreover, all patients in this study and two normal controls demonstrated the same homozygous sequence variation at introns 10 -11 (c.2053 þ 8G-T, rs6002267) ( Figure 1 ).
Patient 12 (B-3444 -13 in our previous study) 3 showing the EP300 gene mutation was first diagnosed with 'mild variant but unquestionably' RSTS by the late Professor Frank Majewski, Universitätsklinikum Düsseldorf, Germany, who assessed in 2001 that 'y of all patients with RSTS whom I have seen (indeed many), she is by far the best as regards intelligence. All others were mentally retarded, but this is certainly not true for this patient. Therefore one would y rather expect an atypical mutation.' [y Von allen Patienten mit RTS, die ich bisher gesehen habe (wirklich zahlreich!), ist sie mit Abstand die beste, was die Intelligenz betrifft. Alle anderen waren geistig behindert, was bei dieser Patientin sicher nicht zutrifft. Insofern ist y eher mit einer atypischen Mutation zu rechnen.] At the age of 14 years and 3 months she presented with microcephaly (occipitofrontal circumference 49.5 cm, À3.2 SD) and a very beaked nose, columella below alae nasi, narrow high-arched palate, a very pronounced overbite with the maxillary incisors markedly protruding over the lower lip, and retrognathia. She had mild myopia (À1 D) and broad thumbs and big toes. Height (152.8 cm, À1.4 SD) was normal and intelligence was borderline normal. At age 18 years, the pronounced overbite was corrected by maxillary surgery. She attended an integrated school for the learning disabled, but after 10 classes failed in the final examination. Vocational training was viewless and she now works in a workshop for the mentally handicapped (estimated IQ B75). The family provided full-length portraits to one of us (OB) but denied permission to publication. The photos EP300 gene mutation and RSTS N Zimmermann et al showed no classical RSTS, as also evident from the pronounced overbite and orthodontic surgery performed here.
Discussion
The c.7100delC deletion in exon 31 represents the fourth disease-associated mutation in EP300 reported to date and the first confirmation of the results of Roelfsema et al 4 It predicts a premature stop codon, p.P2366fsX2401, and a protein truncation towards the 3 0 -end (normal size, 2414 residues). Roelfsema et al 4 described two EP300 mutations (one nonsense, one frameshift) predicting small truncated proteins without the HAT domain, and a third mutation probably deleting essential parts of the EP300 promotor region and probably not resulting in any protein at all. The c.7100delC deletion occurred de novo and in all likelihood represents the causative mutation in our patient, not a polymorphism. Frameshift and nonsense mutations affecting the HAT domain represent the most frequent mutation types observed in RSTS with the CREBBP 1 -3,5,6 and EP300 4 genes. However, the location of the present frameshift EP300 gene mutation and RSTS N Zimmermann et al mutation very close to the 3 0 -end of EP300 is interesting; 3, 5, 6, 11, 16 it leads to a putative very mild truncation that does not alter the HAT domain, and could possibly explain the non-classical RSTS (unusual face, relatively good intelligence) in our patient. An overbite with the maxillary incisors markedly protruding over the lower lip and requiring maxillary surgery is an unusual feature in RSTS. 17 We identified only one EP300 mutation in this series of 38 patients, or B2.6%, a frequency corresponding well with the previous report of B3.2% EP300 mutations. 4 Considering the similar genetic properties and functions of CREBBP (31 exons, 2442 residues) and EP300 (31 exons, 2414 residues), one might expect similar rates of mutations and similar sites of pathogenic mutations. Hence, the 20-fold difference (52.6 vs 2.6%) between the rates of detectable mutations in CREBBP and EP300 in our patients strongly suggests that EP300 plays only a minor role in the etiology of RSTS. The relatively low total number of mutations identified in CREBBP and EP300 (60%, considering the most stringent diagnostic group A) could be in support of further genetic heterogeneity in RSTS.
Furthermore we detected in the EP300 gene five SNPs (Table 2 ; two non-synonymous SNPs, a synonymous SNP and two intronic variants). Addressing the lower rate of pathogenic mutations in EP300 as compared to CREBBP, Roelfsema et al 4 discussed the possibility of different chances of mutations occurring in these two genes, despite their very similar genetic composition (31 coding exons, B2400 residues). Alternatively, mutation rates could be similar and the vast majority of individuals with EP300 mutations could demonstrate phenotypes other than RSTS.
In our previous study, 3 we identified 15 different SNPs in CREBBP in 38 patients (0.39 per individual) and here we detected five different EP300 SNPs in 13 patients (0.38 per individual), a finding supporting approximately equal mutation rates in the two genes. However, the 13 patients in this study demonstrated a total of 29 SNPs in EP300 (Table 2) , or 2.23 per individual, as compared to 27 CREBBP polymorphisms in 38 patients, or 0.71 per individual, identified in our previous study. 3 Hence, EP300 polymorphisms were present at higher frequencies (Wilcoxon test, po0.001). The higher frequencies of the EP300 SNPs could possibly reflect differences in genetic drift of the different polymorphisms. Taken together, our data support that EP300 mutations should be roughly about as frequent as CREBBP mutations, but some could lead to other phenotypes, not classical RSTS. Similarly, the very different frequencies of CREBBP and EP300 mutations with the RSTS phenotype and the observed (although not very striking) phenotypical differences with the EP300 mutations 4 (also this study) suggest that mutations in EP300 could be underdiagnosed due to phenotypes different from classical RSTS. A possible explanation could be the different functions of CREBBP and EP300 during embryogenesis. 7, 9, 18 Finally, a homozygous sequence variation (EP300 c.2053 þ 8T) was present in all individuals studied and hence most likely represents the wild-type sequence. We therefore suggest that the guanine at position 8 of the exon 10 splice donor in the current version of the human genome reference sequence represents a polymorphism.
